Research memoCharles River Laboratories International, Inc. (CRL) · NYSEMemo of October 24, 2026

Charles River earnings

MyStockButler's October 2026 analysis: Charles River next results are expected on November 4, 2026. Watch DSA bookings, study starts and conversion into recognized revenue.

November 4, 2026
Next results
1,004,078
Revenue, quarter to Jun 2026 (US$ thousands; EPS in US$)
-0.03
EPS, diluted, quarter to Jun 2026
Read the full Charles River memoYour first report is free · no card
Every number traced to Charles River's filings8 chapters · 23,131 words225 sources cited

What has Charles River guided for 2026?

For 2026, management guides to 0.0%–1.0% organic revenue growth and adjusted EPS of $11.15–$11.45. Reported revenue is still expected to decline because of divestitures. For 2027–2030, management targets 5%–7% average annual organic growth and low-double-digit adjusted EPS growth. Delivery depends on conversion, utilization, and savings.

Revenue by quarter (US$ thousands; EPS in US$)1,009,763Sep 20241,002,549Dec 2024984,168Mar 20251,032,135Jun 20251,004,852Sep 2025994,227Dec 2025995,830Mar 20261,004,078Jun 2026Revenue
Guidance in forceUS$ millions except per-share amounts and percentages
period guidedlowhighdate given
Revenue growth/(decrease), reportedYear to Dec 2026-3.5%-2.5%Aug 5, 2026
Revenue growth/(decrease), organicYear to Dec 20260.0%1.0%Sep 24, 2026
GAAP EPS estimateYear to Dec 20263.053.35Aug 5, 2026
Free cash flow (FCF)Year to Dec 2026400420Aug 5, 2026
Capital expenditures (capex)Year to Dec 2026200200Aug 5, 2026
Non-GAAP EPSQuarter to Sep 20262.903.00Aug 5, 2026

What this means. The company’s reported earnings per share estimate is much lower than its adjusted estimate because the adjusted figure leaves out acquisition, divestiture, and restructuring costs.

Has Charles River kept its promises?

Guidance reliability is mixed. CRL’s record is 3/5: reported revenue and adjusted EPS each missed their initial ranges twice, while organic revenue missed once. It met or beat every final range reviewed, but that is stronger evidence of near-term forecasting than of long-range planning. Management’s 2027–2030 targets call for 5%–7% average annual organic growth and low-double-digit adjusted EPS growth, which makes the next question whether analysts see the same recovery.

Promises kept: 3/5
What management forecastCheckedAboveWithinBelow
Revenue growth, reported5 years212
Revenue growth, organic5 years221
Non-GAAP EPS estimate5 years212

What do Charles River's last eight quarters show?

The company earns revenue through Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions. Revenue rose from $3.5 billion in 2021 to $4.0 billion in 2025. Reported growth slowed sharply by 2023 and turned negative in both 2024 and 2025.

The last eight quartersUS$ thousands; EPS in US$
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,004,078995,830994,2271,004,8521,032,135984,1681,002,5491,009,763
Gross margin36.2%29.6%31.1%33.7%34.6%32.3%28.4%34.6%
Operating income119,888119,897-283,440133,799100,13474,669-167,687117,405
Net income-1,482-14,843-276,55554,42252,32625,469-214,49569,657
EPS, diluted-0.03-0.30-5.621.101.060.50-4.221.33
= Free cash flow148,620-14,83158,570178,246169,305112,37383,746213,071

What this means. The company lost money in June 2026 because selling two businesses caused a large one-time loss, even though its main business was profitable.

What should I watch in Charles River's next results?

CRL’s next results call is scheduled for November 4, 2026, at 9 a.m. Eastern time. The third-quarter outlook calls for organic revenue growth of 1.0%–3.0% and adjusted EPS of $2.90–$3.00. That makes the report a concrete test of the recovery.

The operating evidence should come from DSA. Investors should watch bookings, study starts and the conversion of work into recognized revenue. Management expects recent demand to extend into 2027, but a backlog is less valuable if customers repeatedly postpone the work.

From the full memo · 1. The business

Charles River Laboratories is a behind-the-scenes supplier to medicine: it sells research animals, scientific studies, and quality tests to companies developing or making products. Its dollars come in when customers buy those goods and services, and go out through scientists, animal care, facilities, suppliers, and the investment needed to keep the work running.

Continue reading, free
Your first report is free · no card

Where these numbers come from

More on Charles River

Charles River stock forecastAuf Deutsch

Its rivals

Labcorp (LH)IQVIA (IQV)Thermo Fisher (TMO)WuXi AppTec (2359.HK)

Browse

All stocksS&P 500 companiesCompanies C
The full Charles River memoYour first report is free
Read it